Arango, C., Buitelaar, J. K., Fegert, J. M., Olivier, V., Pénélaud, P., Marx, U., Chimits, D., Falissard, B., , , Barylnik, J., Birdeanu, L., Bosch, G. P., Boychevskaya, J., Boyev, I., Bugán, E., Bukhanovskaya, O., Chaban, O., Dobrescu, I., Feller, G., Flisiak-Antonijczuk, H., Gácser, M., Grigorieva, E., Holttinen, T., Ivanovic-Kovacevic, S., Kapornai, K., Kasimova, L., Koren, E., Martsenkovsky, I., Maruta, N. O., Matican, M., Matkovska, T., Melnyk, E., Milovancevic, M. P., Mostova, O., Nagy, P., Nussbaum, L., Petrov, P., Pietraszczyk-Kedziora, B., Polnareva, N., Predescu, E., Razsolkova, V., Rybakowski, F., Rymsha, S., Schrönen, J. P., Shigashov, D., Skrypnikov, A., Stankovic, M., Stevanovic, D., Timonen, M., Väänänen, J., van der Westhuizen, J., van Niekerk, G., Venger, O., Voloshchuk, A., & Wolañczyk, T. (2022). safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. Lancet, 9, 113–124. http://access.bl.uk/ark:/81055/vdc_100178306018.0x000001